The clinical question

This research direction addresses the need for better approaches to progressive lung fibrosis. The program investigates local pulmonary delivery and the relationship between payload activity, tissue exposure and fibrotic responses.

Our research approach

The program explores extracellular vesicles (EVs) associated with Decorin. Payload configuration, vesicle association, potency and preservation of function after aerosolization require product-specific validation.

Current development focus

Product configuration and preclinical evaluation remain in development. The engineered Decorin–EV candidate is distinct from unmodified MSC-derived EVs and from live Decorin-expressing MSCs; evidence cannot be assumed to transfer between them. No completed clinical filing or human efficacy is claimed for this candidate.

Questions that guide development

  • Is the active Decorin payload associated with the intended EV fraction?
  • Is biological activity preserved after aerosolization?
  • Can added activity, batch consistency and repeat-dose tolerability be demonstrated?
This is an investigational research program. No clinical efficacy, completed clinical filing or commercial authorization is implied.